Antibodies, Immunity, and COVID-19.
作者信息
Spellberg Brad, Nielsen Travis B, Casadevall Arturo
机构信息
Los Angeles County + University of Southern California Medical Center, Los Angeles.
Department of Public Health Sciences, Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, Illinois.
出版信息
JAMA Intern Med. 2021 Apr 1;181(4):460-462. doi: 10.1001/jamainternmed.2020.7986.
Abstract
摘要
相似文献
1
Antibodies, Immunity, and COVID-19.抗体、免疫与2019冠状病毒病
JAMA Intern Med. 2021 Apr 1;181(4):460-462. doi: 10.1001/jamainternmed.2020.7986.
2
SARS-CoV-2 immunity and HIV infection: total recall?新型冠状病毒2型免疫与HIV感染：全面回顾？
Lancet HIV. 2021 Jun;8(6):e312-e313. doi: 10.1016/S2352-3018(21)00097-7. Epub 2021 Apr 29.
3
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.血清学检测评估康复的新冠肺炎患者中高度可变的新冠病毒中和抗体活性。
J Clin Microbiol. 2020 Nov 18;58(12). doi: 10.1128/JCM.02005-20.
4
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.针对 SARS-CoV-2 刺突受体结合域和核衣壳的异源抗体及其对 COVID-19 免疫的影响。
JCI Insight. 2020 Sep 17;5(18):142386. doi: 10.1172/jci.insight.142386.
5
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.SARS-CoV-2 特异性中和抗体反应在 COVID-19 大流行第一波后挪威医护人员中的前瞻性队列研究。
J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737.
6
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.新型冠状病毒中和抗体与商业血清学检测的相关性。
Clin Chem. 2020 Dec 1;66(12):1538-1547. doi: 10.1093/clinchem/hvaa211.
7
Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.新冠肺炎患者血清中数月来持续存在对 SARS-CoV-2 的中和活性。
Viruses. 2020 Nov 27;12(12):1357. doi: 10.3390/v12121357.
8
SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.在犹太教堂社区爆发的 SARS-CoV-2：抗 SARS-CoV-2 IgG 反应的持久性和强度。
Epidemiol Infect. 2021 Jun 24;149:e153. doi: 10.1017/S0950268821001369.
9
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.新型冠状病毒血清中和抗体的持续时间：严重急性呼吸综合征冠状病毒感染的经验教训。
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.
10
Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.沙特阿拉伯医护人员中 SARS-CoV-2（COVID-19）的血清流行率：病例对照医院比较。
Diagn Microbiol Infect Dis. 2021 Mar;99(3):115273. doi: 10.1016/j.diagmicrobio.2020.115273. Epub 2020 Nov 20.
引用本文的文献
1
Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers.爆发性发热患儿的 SARS-CoV-2 预流行期抗体筛查和病毒检测。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241260633. doi: 10.1177/03946320241260633.
2
Evaluation of antibody titers in COVID-19 patients with cerebral or pulmonary symptoms and mild symptoms.对出现脑部或肺部症状以及轻症的新冠肺炎患者的抗体滴度进行评估。
Iran J Microbiol. 2024 Feb;16(1):124-131. doi: 10.18502/ijm.v16i1.14881.
3
High seroprevalence of severe acute respiratory syndrome coronavirus 2 among healthcare workers in Yaoundé, Cameroon after the first wave of Covid-19 pandemic and associated factors.喀麦隆雅温得医护人员在第一波 COVID-19 大流行后严重急性呼吸综合征冠状病毒 2 的高血清阳性率及相关因素。
Influenza Other Respir Viruses. 2024 Feb;18(2):e13239. doi: 10.1111/irv.13239.
4
Pathways to Immunity: Patterns of Excess Death Across the United States and Within Closed Religious Communities.免疫途径：美国各地和封闭宗教社区超额死亡模式。
J Relig Health. 2023 Aug;62(4):2820-2835. doi: 10.1007/s10943-023-01838-z. Epub 2023 Jun 1.
5
Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.接种 SARS-CoV-2 疫苗后老年类风湿关节炎患者的抗 S1/RBD 特异性抗体形成：单中心前瞻性观察性研究。
J Korean Med Sci. 2023 Apr 10;38(14):e109. doi: 10.3346/jkms.2023.38.e109.
6
Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors.天然灵感来源的新型冠状病毒2抑制剂的设计与合成
RSC Med Chem. 2023 Jan 25;14(3):507-519. doi: 10.1039/d2md00149g. eCollection 2023 Mar 22.
7
Enzymatic approaches against SARS-CoV-2 infection with an emphasis on the telomere-associated enzymes.针对 SARS-CoV-2 感染的酶法治疗策略，重点关注端粒相关酶。
Biotechnol Lett. 2023 Mar;45(3):333-345. doi: 10.1007/s10529-023-03352-4. Epub 2023 Jan 28.
8
Framing the future of the COVID-19 response operations in 2022 in the WHO African region.为 2022 年世卫组织非洲区域的 COVID-19 应对行动规划未来。
Glob Health Action. 2022 Dec 31;15(1):2130528. doi: 10.1080/16549716.2022.2130528.
9
Laboratory Findings in Different Disease Status of COVID-19 Admitted Patients at Dilla University Referral Hospital Treatment Center, South Ethiopia.埃塞俄比亚南部迪拉大学转诊医院治疗中心收治的新冠肺炎患者不同疾病状态下的实验室检查结果
Infect Drug Resist. 2022 Aug 8;15:4307-4320. doi: 10.2147/IDR.S370907. eCollection 2022.
10
Pulmonary embolism with junctional tachycardia: A serious complication after COVID-19 vaccination.伴有交界性心动过速的肺栓塞：新冠病毒疫苗接种后的一种严重并发症。
Ann Med Surg (Lond). 2022 Aug;80:103983. doi: 10.1016/j.amsu.2022.103983. Epub 2022 Jun 28.
本文引用的文献
1
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.截至 2020 年 9 月美国估计的 SARS-CoV-2 血清流行率。
JAMA Intern Med. 2021 Apr 1;181(4):450-460. doi: 10.1001/jamainternmed.2020.7976.
2
Genomic evidence for reinfection with SARS-CoV-2: a case study.基因组证据表明 SARS-CoV-2 再次感染：一项案例研究。
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
3
COVID-19 herd immunity: where are we?COVID-19 群体免疫：我们在哪里？
Nat Rev Immunol. 2020 Oct;20(10):583-584. doi: 10.1038/s41577-020-00451-5.
4
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.性别、年龄和住院情况会影响 COVID-19 恢复期血浆捐献者人群的抗体反应。
J Clin Invest. 2020 Nov 2;130(11):6141-6150. doi: 10.1172/JCI142004.
5
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.2020年3月23日至5月12日美国10个地点针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的血清流行率
JAMA Intern Med. 2020 Jul 21. doi: 10.1001/jamainternmed.2020.4130.
6
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.西班牙 2020 年人群血清流行病学研究（ENE-COVID）：全国范围内基于人群的血清流行病学研究。
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
7
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.2020 年 4 月 6 日，意大利伦巴第大区洛迪红区献血者中 SARS-CoV-2 特异性中和抗体的流行情况。
Euro Surveill. 2020 Jun;25(24). doi: 10.2807/1560-7917.ES.2020.25.24.2001031.
8
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.源自1918年流感大流行幸存者B细胞的中和抗体。
Nature. 2008 Sep 25;455(7212):532-6. doi: 10.1038/nature07231. Epub 2008 Aug 17.
9
Antibodies and B cell memory in viral immunity.病毒免疫中的抗体与B细胞记忆
Immunity. 2007 Sep;27(3):384-92. doi: 10.1016/j.immuni.2007.09.002.
Zotero 插件